Tyrosine Protein Kinase JAK1 - Pipeline Review, H1 2020
Tyrosine Protein Kinase JAK1 - Pipeline Review, H1 2020
SUMMARY
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 42 molecules. Out of which approximately 41 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase JAK1 - Pipeline Review, H1 2020, outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body.
The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 6, 12, 2, 2, 15 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders, Respiratory, Central Nervous System, Ophthalmology, Cardiovascular, Genetic Disorders, Hematological Disorders, Infectious Disease, Metabolic Disorders and Women's Health which include indications Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Alopecia Areata, Ulcerative Colitis, Crohn’s Disease (Regional Enteritis), Vitiligo, Inflammatory Bowel Disease, Systemic Lupus Erythematosus, Asthma, Diffuse Large B-Cell Lymphoma, Graft Versus Host Disease (GVHD), Myelodysplastic Syndrome, Myelofibrosis, Peripheral T-Cell Lymphomas (PTCL), Psoriasis, Psoriatic Arthritis, Triple-Negative Breast Cancer (TNBC), Anaplastic Large Cell Lymphoma (ALCL), Ankylosing Spondylitis (Bekhterev's Disease), B-Cell Non-Hodgkin Lymphoma, Bronchiolitis Obliterans, Chronic Lymphocytic Leukemia (CLL), Dermatitis (Eczema), Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Head And Neck Cancer Squamous Cell Carcinoma, Hidradenitis Suppurativa, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Inflammation, Lymphoma, Mantle Cell Lymphoma, Multiple Sclerosis, Non-Small Cell Lung Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Relapsed Multiple Myeloma, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Thrombocythemia Myelofibrosis, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Aicardi-Goutieres Syndrome (AGS), Androgenic Alopecia, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Anterior Uveitis, Arthritis, Auto Inflammatory Disease, B-Cell Chronic Lymphocytic Leukemia, Breast Hyperplasia, Chronic Cutaneous Lupus Erythematosus (CCLE)/Discoid Lupus Erythematosus (DLE), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Myelomonocytic Leukemia (CMML), Colon Cancer, Colorectal Cancer, Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Dermatomyositis, Diabetic Macular Edema, Endometrial Cancer, Epstein-Barr Virus (HHV-4) Infections, Essential Thrombocythemia, Follicular Lymphoma, Gastric Cancer, Hairy Cell Leukemia, Hypereosinophilic Syndrome, Hypopharyngeal Cancer, Juvenile Arthritis, Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Leiomyosarcoma, Lung Transplant Rejection, Lupus Erythematosus, Lupus Nephritis, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Prostate Cancer, Multiple Myeloma (Kahler Disease), Myeloproliferative Disorders, Myxoid Liposarcoma, Non-Hodgkin Lymphoma, Oligoarticular Idiopathic Juvenile Arthritis, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Polyarticular Juvenile Idiopathic Arthritis (PJIA), Polycythemia Vera, Polymyalgia Rheumatica (PMR), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Myelofibrosis, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Sicca Syndrome (Sjogren), Skin Cancer, Spondyloarthritis (Spondyloarthropathy), Synovial Sarcoma, Systemic Idiopathic Juvenile Arthritis, Takayasu Arteritis, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Uveitis.
Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 42 molecules. Out of which approximately 41 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase JAK1 - Pipeline Review, H1 2020, outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body.
The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 6, 12, 2, 2, 15 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders, Respiratory, Central Nervous System, Ophthalmology, Cardiovascular, Genetic Disorders, Hematological Disorders, Infectious Disease, Metabolic Disorders and Women's Health which include indications Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Alopecia Areata, Ulcerative Colitis, Crohn’s Disease (Regional Enteritis), Vitiligo, Inflammatory Bowel Disease, Systemic Lupus Erythematosus, Asthma, Diffuse Large B-Cell Lymphoma, Graft Versus Host Disease (GVHD), Myelodysplastic Syndrome, Myelofibrosis, Peripheral T-Cell Lymphomas (PTCL), Psoriasis, Psoriatic Arthritis, Triple-Negative Breast Cancer (TNBC), Anaplastic Large Cell Lymphoma (ALCL), Ankylosing Spondylitis (Bekhterev's Disease), B-Cell Non-Hodgkin Lymphoma, Bronchiolitis Obliterans, Chronic Lymphocytic Leukemia (CLL), Dermatitis (Eczema), Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Head And Neck Cancer Squamous Cell Carcinoma, Hidradenitis Suppurativa, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Inflammation, Lymphoma, Mantle Cell Lymphoma, Multiple Sclerosis, Non-Small Cell Lung Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Relapsed Multiple Myeloma, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Thrombocythemia Myelofibrosis, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Aicardi-Goutieres Syndrome (AGS), Androgenic Alopecia, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Anterior Uveitis, Arthritis, Auto Inflammatory Disease, B-Cell Chronic Lymphocytic Leukemia, Breast Hyperplasia, Chronic Cutaneous Lupus Erythematosus (CCLE)/Discoid Lupus Erythematosus (DLE), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Myelomonocytic Leukemia (CMML), Colon Cancer, Colorectal Cancer, Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Dermatomyositis, Diabetic Macular Edema, Endometrial Cancer, Epstein-Barr Virus (HHV-4) Infections, Essential Thrombocythemia, Follicular Lymphoma, Gastric Cancer, Hairy Cell Leukemia, Hypereosinophilic Syndrome, Hypopharyngeal Cancer, Juvenile Arthritis, Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Leiomyosarcoma, Lung Transplant Rejection, Lupus Erythematosus, Lupus Nephritis, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Prostate Cancer, Multiple Myeloma (Kahler Disease), Myeloproliferative Disorders, Myxoid Liposarcoma, Non-Hodgkin Lymphoma, Oligoarticular Idiopathic Juvenile Arthritis, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Polyarticular Juvenile Idiopathic Arthritis (PJIA), Polycythemia Vera, Polymyalgia Rheumatica (PMR), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Myelofibrosis, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Sicca Syndrome (Sjogren), Skin Cancer, Spondyloarthritis (Spondyloarthropathy), Synovial Sarcoma, Systemic Idiopathic Juvenile Arthritis, Takayasu Arteritis, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Uveitis.
Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AbbVie Inc
Aclaris Therapeutics Inc
Astellas Pharma Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
CJ HealthCare Corp
Concert Pharmaceuticals Inc
Dizal (Jiangsu) Pharmaceutical Co Ltd
Eli Lilly and Co
Galapagos NV
Han Wha Pharma Co Ltd
Hangzhou East China Pharmaceutical Group Co Ltd
Incyte Corp
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
Merck & Co Inc
Nissan Chemical Corp
Pfizer Inc
Portola Pharmaceuticals Inc
Sareum Holdings Plc
Sierra Oncology Inc
Simcere Pharmaceutical Group
Theravance Biopharma Inc
Wuxi Fuxin Pharmaceutical Research and Development Co Ltd
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Drug Profiles
ABBV-599 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
abrocitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Appendix
Global Markets Direct Report Coverage
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AbbVie Inc
Aclaris Therapeutics Inc
Astellas Pharma Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
CJ HealthCare Corp
Concert Pharmaceuticals Inc
Dizal (Jiangsu) Pharmaceutical Co Ltd
Eli Lilly and Co
Galapagos NV
Han Wha Pharma Co Ltd
Hangzhou East China Pharmaceutical Group Co Ltd
Incyte Corp
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
Merck & Co Inc
Nissan Chemical Corp
Pfizer Inc
Portola Pharmaceuticals Inc
Sareum Holdings Plc
Sierra Oncology Inc
Simcere Pharmaceutical Group
Theravance Biopharma Inc
Wuxi Fuxin Pharmaceutical Research and Development Co Ltd
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Drug Profiles
ABBV-599 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
abrocitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..5), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1)
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Companies, H1 2020 (Contd..8), H1 2020
Products under Development by Companies, H1 2020 (Contd..9), H1 2020
Products under Development by Companies, H1 2020 (Contd..10), H1 2020
Products under Development by Companies, H1 2020 (Contd..11), H1 2020
Products under Development by Companies, H1 2020 (Contd..12), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AbbVie Inc, H1 2020
Pipeline by Aclaris Therapeutics Inc, H1 2020
Pipeline by Astellas Pharma Inc, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by CJ HealthCare Corp, H1 2020
Pipeline by Concert Pharmaceuticals Inc, H1 2020
Pipeline by Dizal (Jiangsu) Pharmaceutical Co Ltd, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by Galapagos NV, H1 2020
Pipeline by Han Wha Pharma Co Ltd, H1 2020
Pipeline by Hangzhou East China Pharmaceutical Group Co Ltd, H1 2020
Pipeline by Incyte Corp, H1 2020
Pipeline by Japan Tobacco Inc, H1 2020
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by Nissan Chemical Corp, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Portola Pharmaceuticals Inc, H1 2020
Pipeline by Sareum Holdings Plc, H1 2020
Pipeline by Sierra Oncology Inc, H1 2020
Pipeline by Simcere Pharmaceutical Group, H1 2020
Pipeline by Theravance Biopharma Inc, H1 2020
Pipeline by Wuxi Fuxin Pharmaceutical Research and Development Co Ltd, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020
Discontinued Products, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..5), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1)
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Companies, H1 2020 (Contd..8), H1 2020
Products under Development by Companies, H1 2020 (Contd..9), H1 2020
Products under Development by Companies, H1 2020 (Contd..10), H1 2020
Products under Development by Companies, H1 2020 (Contd..11), H1 2020
Products under Development by Companies, H1 2020 (Contd..12), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AbbVie Inc, H1 2020
Pipeline by Aclaris Therapeutics Inc, H1 2020
Pipeline by Astellas Pharma Inc, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by CJ HealthCare Corp, H1 2020
Pipeline by Concert Pharmaceuticals Inc, H1 2020
Pipeline by Dizal (Jiangsu) Pharmaceutical Co Ltd, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by Galapagos NV, H1 2020
Pipeline by Han Wha Pharma Co Ltd, H1 2020
Pipeline by Hangzhou East China Pharmaceutical Group Co Ltd, H1 2020
Pipeline by Incyte Corp, H1 2020
Pipeline by Japan Tobacco Inc, H1 2020
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by Nissan Chemical Corp, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Portola Pharmaceuticals Inc, H1 2020
Pipeline by Sareum Holdings Plc, H1 2020
Pipeline by Sierra Oncology Inc, H1 2020
Pipeline by Simcere Pharmaceutical Group, H1 2020
Pipeline by Theravance Biopharma Inc, H1 2020
Pipeline by Wuxi Fuxin Pharmaceutical Research and Development Co Ltd, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020
Discontinued Products, H1 2020 (Contd..1), H1 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
COMPANIES MENTIONED
AbbVie Inc
Aclaris Therapeutics Inc
Astellas Pharma Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
CJ HealthCare Corp
Concert Pharmaceuticals Inc
Dizal (Jiangsu) Pharmaceutical Co Ltd
Eli Lilly and Co
Galapagos NV
Han Wha Pharma Co Ltd
Hangzhou East China Pharmaceutical Group Co Ltd
Incyte Corp
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
Merck & Co Inc
Nissan Chemical Corp
Pfizer Inc
Portola Pharmaceuticals Inc
Sareum Holdings Plc
Sierra Oncology Inc
Simcere Pharmaceutical Group
Theravance Biopharma Inc
Wuxi Fuxin Pharmaceutical Research and Development Co Ltd
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
COMPANIES MENTIONED
AbbVie Inc
Aclaris Therapeutics Inc
Astellas Pharma Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
CJ HealthCare Corp
Concert Pharmaceuticals Inc
Dizal (Jiangsu) Pharmaceutical Co Ltd
Eli Lilly and Co
Galapagos NV
Han Wha Pharma Co Ltd
Hangzhou East China Pharmaceutical Group Co Ltd
Incyte Corp
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
Merck & Co Inc
Nissan Chemical Corp
Pfizer Inc
Portola Pharmaceuticals Inc
Sareum Holdings Plc
Sierra Oncology Inc
Simcere Pharmaceutical Group
Theravance Biopharma Inc
Wuxi Fuxin Pharmaceutical Research and Development Co Ltd
